

Publisher: Bentham Science Publishers
E-ISSN: 1875-628x|6|3|186-192
ISSN: 1570-1808
Source: Letters in Drug Design & Discovery, Vol.6, Iss.3, 2009-04, pp. : 186-192
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content




Arylsulphonamide hydroxamic acids as potent inhibitors of MMP-13
Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 9, 1999-09 ,pp. :






Hydroxamic Acids as Pharmacological Agents
Current Medicinal Chemistry, Vol. 9, Iss. 17, 2002-09 ,pp. :